Breast Cancer Clinical Trials

Find Breast Cancer Clinical Trials Near You

Refusal of Sentinel Lymph Node Biopsy in Patients With Luminal A Subtype Early Breast Cancer

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Sentinel lymph node biopsy (SLNB) is the standard of axillary lymph node surgical staging in patients with early breast cancer. The main goal of the study is to abandon axillary surgery in patients over 59 years old with early, luminal A, clinical lymph node negative breast cancer.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 60
Healthy Volunteers: f
View:

• HER2-negative breast cancer (ER +/ PR +), Ki67 \<= 30%, G1-2

• age\> 59 years.

• morphologically confirmed diagnosis of breast cancer, IA-IIA stage

• ECOG score 0-2.

• the absence of contraindications to surgical intervention (including anesthetic risk is taken into account).

• patient is able to provide informed consent and sign approved consent forms to participate in the study.

• patients after surgical treatment in the scope of breast resection with sentinel lymph node biopsy (SLNB, group 1) or without axillary surgery (without SLNB, group 2).

• N0 status of axillary lymph nodes according to ultrasound and SPECT-CT of the breast with 99mTc-Technetril.

Locations
Other Locations
Russian Federation
N.N. Petrov National Medical Research Center of Oncology
RECRUITING
Saint Petersburg
Contact Information
Primary
Petr Krivorotko, Degree
dr.krivorotko@mail.ru
+79219597722
Backup
Arina Gorina
dr.arina_olegovna@mail.ru
+79185374992
Time Frame
Start Date: 2023-07-27
Estimated Completion Date: 2027-05-25
Participants
Target number of participants: 100
Treatments
Experimental: Group 2:breast resection without sentinel lymph node biopsy, radiotherapy to the breast area and SLN
1. Prior to the surgical phase of treatment, all patients undergo SPECT-CT of the breasts with 99mTc-Technetril and SPECT-CT of the sentinel lymph nodes with Tc99m-colloid. A sectoral resection of the breast is performed according to the standard technique, with subsequent histological examination of the excised tissue. Surgical staging using sentinel lymph node biopsy is not performed.~2. In the next phase, 4-12 weeks after surgery, 3D conformal radiotherapy is administered to the remaining breast tissue, including the region of the sentinel lymph nodes as identified by the preoperative SPECT-CT of the sentinel lymph nodes with Tc99m-colloid. Radiation planning is carried out according to ESTRO protocols, modified in accordance with the atlas of the sentinel lymph nodes.~3. Based on the postoperative histological findings, adjuvant systemic therapy is prescribed to the patient in accordance with current clinical guidelines.
Active_comparator: Group 1: Breast resection with biopsy of the sentinel lymph node, radiotherapy
1. Prior to surgical treatment all patients undergo breast SPECT-CT using 99mTc-Technetril and SPECT-CT of the SLN using Tc99m-colloid. The patient then undergoes a sectoral resection of the breast with a sentinel lymph node biopsy, followed by histological analysis of the excised tissue.~2. In the next stage, 3D conformal RT is administered to the remaining breast tissue 4 to 12 weeks after the surgical treatment. In patients who have undergone SLNB, only the remaining breast tissue is irradiated, without irradiation of the axillary region, provided that the postoperative histological examination shows no evidence of sentinel lymph node involvement. If metastatic involvement of the SLN is detected, additional RT of the axillary region is performed. Radiation planning is carried out in accordance with ESTRO protocols.~3. Based on the postoperative histological findings, the patient is prescribed adjuvant systemic therapy in accordance with current clinical guidelines.
Related Therapeutic Areas
Sponsors
Leads: N.N. Petrov National Medical Research Center of Oncology

This content was sourced from clinicaltrials.gov